Chemical | 05 June 2021
Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The company ramp ups manufacturing capacity of ethyl acetate from 87,000 MT per annum to 100,000 MT per annum
TA’ZIZ will accelerate the UAE’s broader economic growth and industrial diversification, with initial chemical production expected in 2025
Elastopir PH 1132/509/0 is a n-pentane-blown foam, with a low global warming and ozone depletion potential
The parties will consider the possibility of SIBUR’s engagement in the ongoing project for construction of an integrated gas chemical complex to produce polypropylene with an annual capacity of 500 kt
Leverage global R&D expertise and apply local R&D flexibility to provide best-fit solutions
The global raw material environment continues to demonstrate significant inflationary pressures
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
The company wants to leverage on its capabilities and global leadership position in Pyridine, Picoline and Diketene chemistries
Croda has acquired a controlling majority 95.6% of Parfex’s outstanding shares
Company has signed definitive agreement to buy IM Chemicals, a leading provider of specialty chemical products serving the pharmaceutical, coatings, and fuel & lubricant markets
The cutting-edge laboratory will complement the existing network of research and application centers dedicated to Arkema’s Coating Solutions so that to Arkema’s performance additives
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
The acquisition will help the company to expands its operations in agrochemicals and oil & gas thereby providing incremental value to its stakeholders
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
Production will start in 2022
Subscribe To Our Newsletter & Stay Updated
_195_291.jpg)
